ببتيدات البحث BPC-157 وTB-500 لدراسات الأنسجة

BPC-157 is a synthetic pentadecapeptide derived from a protective protein sequence found in human gastric juice, and it has been investigated in preclinical models for themes related to angiogenesis, tissue recovery, and signaling in injury models. TB-500 refers to a short synthetic fragment of Thymosin Beta-4 — most commonly the Ac-LKKTETQ-NH2 heptapeptide — studied for actin-binding related mechanisms. Because BPC-157 and TB-500 act through different reported pathways, combination research designs must document each construct independently.

Catalog buyers should be precise about which construct a vendor is supplying: full-length Thymosin Beta-4 (43 amino acids) is not interchangeable with the TB-500 fragment, and BPC-157 salts or acetate forms must be identified by the CoA. Sequence confirmation is the first checkpoint before any protocol work.

When sourcing BPC-157 or TB-500 for tissue and cell studies, the documentation package matters as much as the peptide itself. A complete lot file should include: an HPLC purity profile (commonly ≥95% as a research-grade baseline), identity confirmation by mass spectrometry or equivalent, the exact sequence and salt form, residual solvent and appearance checks, and a batch-specific CoA matching the lot number on the vial label.

Stability assumptions should also be documented: lyophilized peptides are typically stored cold and dry, protected from light and moisture, and reconstituted only under the laboratory's own SOP. Recording storage conditions at receipt protects the validity of downstream results and supports reproducibility reporting.

Multi-peptide research protocols that combine BPC-157 with TB-500 (sometimes described as stacks) require the same documentation rigor as any combination study. Each component should have its own CoA, lot traceability, and reconstitution record, because batch variations in either construct can confound the experimental interpretation.

Helix Peptide offers both individual BPC-157 and TB-500 lots as well as a pre-mixed stack SKU for protocol convenience. For the pre-mixed SKU, the CoA documents component identity and ratio per lot — buyers designing dose-response or pathway studies should confirm the supplied ratio matches their protocol assumptions before ordering.